39,271 Shares in Progyny, Inc. $PGNY Purchased by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. purchased a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 39,271 shares of the company’s stock, valued at approximately $989,000.

Several other hedge funds have also modified their holdings of the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Progyny in the second quarter valued at approximately $29,000. Nykredit A S acquired a new position in Progyny during the second quarter worth $38,000. IFP Advisors Inc grew its holdings in Progyny by 376.0% during the second quarter. IFP Advisors Inc now owns 1,961 shares of the company’s stock worth $57,000 after acquiring an additional 1,549 shares during the period. Toth Financial Advisory Corp purchased a new position in Progyny in the second quarter worth $65,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Progyny in the second quarter worth $74,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. KeyCorp raised their target price on Progyny from $30.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Barclays decreased their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 12th. Citizens Jmp upped their price target on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. Leerink Partners set a $38.00 price target on shares of Progyny in a report on Wednesday, July 22nd. Finally, Canaccord Genuity Group set a $35.00 price target on shares of Progyny in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.36.

Insider Buying and Selling at Progyny

In other news, COO Melissa B. Cummings sold 1,879 shares of the firm’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer owned 66,496 shares in the company, valued at $1,861,888. This trade represents a 2.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of Progyny stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the transaction, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. This trade represents a 4.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 17,282 shares of company stock valued at $475,790. Insiders own 9.90% of the company’s stock.

Progyny Price Performance

Shares of NASDAQ:PGNY opened at $28.97 on Friday. The business’s 50 day simple moving average is $26.62 and its 200-day simple moving average is $25.87. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 31.49, a price-to-earnings-growth ratio of 2.00 and a beta of 1.02. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $33.06.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The business had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same quarter in the prior year, the firm posted $0.19 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities analysts anticipate that Progyny, Inc. will post 1.25 earnings per share for the current year.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.